Patrice X. Petit | Signal Transduction | Best Researcher Award

Published on by Global Scholar Awards

Dr. Patrice X. Petit | signal transduction | Best Researcher Award

 Research director | Centre National de la Recherche Scientifique | France

Dr. Patrice X. Petit, Doctor ès Sciences and PhD in Biology, is a Research Director at the French National Centre for Scientific Research (CNRS), where he has served since 1979 and established an internationally recognized career in cell biology. Trained at the Université Pierre et Marie Curie and the Université Denis Diderot (Paris), his work has focused on the molecular mechanisms governing cell death, mitochondrial dynamics, oxidative stress, and their implications in cancer biology, immunology, and toxicology. Over more than four decades, he has developed a broad international scientific presence through extensive teaching and research collaborations across Europe, North America, and Asia, including academic engagements with institutions such as the Chinese Academy of Sciences, Caltech, UT Southwestern, the Beatson Cancer Research Center in Glasgow, the University of Madrid, and multiple leading universities throughout Scandinavia, Germany, and France. His scientific leadership is further reflected in his service as an elected member (2016–2020) of the Scientific Council of the CNRS Institute of Biological Sciences (INSB). Dr. Petit has authored 134 scientific publications, accumulating approximately 12,500 citations and an h-index of 44, demonstrating sustained research influence across several biomedical domains, including contributions to plant biology. He is an active peer reviewer for major journals such as Cancer Research, Journal of Cell Biology, PNAS, Oncogene, and Cell Death and Differentiation, and he has served as a grant reviewer for major funding bodies, including the Austrian Academy of Sciences, the French National Research Agency (ANR), EMBO, the Swiss National Science Foundation, and the Fondation pour la Recherche Médicale. His interdisciplinary background—ranging from a formal qualification in history (Université Paris Diderot, 1979) to a DIU in rare diseases (Université de Strasbourg, 2017)—underscores both scientific depth and broader intellectual engagement. Through his sustained research output, international collaborations, and service to the scientific community, Patrice X. Petit has contributed significantly to advancing fundamental and translational knowledge in cell biology, with measurable societal impact across biomedical research and education.

Profiles: Google Scholar | Scopus | ORCID

Featured Publications

Zamzami, N., Marchetti, P., Castedo, M., Decaudin, D., Macho, A., Hirsch, T., … Petit, P. X. (1995). Sequential reduction of mitochondrial transmembrane potential and generation of reactive oxygen species in early programmed cell death. The Journal of Experimental Medicine, 182(2), 367–377.

Zamzami, N., Marchetti, P., Castedo, M., Zanin, C., Vayssière, J. L., Petit, P. X., … Kroemer, G. (1995). Reduction in mitochondrial potential constitutes an early irreversible step of programmed lymphocyte death in vivo. The Journal of Experimental Medicine, 181(5), 1661–1672.

Kroemer, G., Petit, P., Zamzami, N., Vayssière, J. L., & Mignotte, B. (1995). The biochemistry of programmed cell death. The FASEB Journal, 9(13), 1277–1287.

Petit, P. X., Lecoeur, H., Zorn, E., Dauguet, C., Mignotte, B., & Gougeon, M. L. (1995). Alterations in mitochondrial structure and function are early events of dexamethasone-induced thymocyte apoptosis. The Journal of Cell Biology, 130(1), 157–167.

Petit, P. X., Susin, S. A., Zamzami, N., Mignotte, B., & Kroemer, G. (1996). Mitochondria and programmed cell death: Back to the future. FEBS Letters, 396(1), 7–13.

Dr. Petit’s work has fundamentally advanced our understanding of mitochondrial biology and programmed cell death, shaping modern concepts of apoptosis, autophagy, and cellular stress responses. His discoveries enabled new biomedical approaches to cancer, immunology, and rare diseases

Imran Shair Mohammad | Drug Delivery | Best Researcher Award

Published on by Global Scholar Awards

Dr. Imran Shair Mohammad | Drug Delivery | Best Researcher Award

Postdoctoral Fellow | City of Hope National Medical Center | United States

Dr. Imran Shair Mohammad is a distinguished pharmaceutical scientist whose research focuses on developing next-generation minimally invasive cancer immunotherapies through the design of innovative drug delivery systems and biomaterials. His work lies at the intersection of drug discovery, mRNA and peptide engineering, and biomaterial science, with an emphasis on creating nano/microparticle and hydrogel-based systems for targeted delivery of exosomes, RNA, peptides, and small molecules to improve therapeutic outcomes in cancer, inflammation, and infectious diseases. He earned his Ph.D. in Pharmaceutics from China Pharmaceutical University, Nanjing, following an M.Phil and Pharm.D. from The Islamia University of Bahawalpur, Pakistan. Professionally, Dr. Mohammad has held several postdoctoral research positions across leading international institutions, including the University of North Carolina at Chapel Hill, Erciyes University in Turkey, Sun Yat-sen University in China, and currently serves at the City of Hope National Medical Center, USA. His expertise spans drug and gene delivery, mRNA and peptide synthesis, protein engineering, and immunomodulatory biomaterials, with hands-on proficiency in nanoparticle development, polymer chemistry, and advanced analytical techniques such as HPLC, TEM, and LC-MS. His research interests encompass cancer immunotherapy, drug resistance, cellular engineering, and microbiome-based therapeutics. Dr. Mohammad has published over 40 peer-reviewed articles, received multiple international research grants from the USA, Turkey, and China, and serves on the editorial boards of Cancer Immunology Connect and Current Drug Delivery. Recognized with prestigious honors such as the High-Level Foreign Talents Award from Guangdong Province and the Chinese Government Ph.D. Scholarship, he continues to contribute to advancing translational nanomedicine and targeted immunotherapeutic strategies. His career exemplifies a commitment to scientific innovation, interdisciplinary collaboration, and impactful research that bridges laboratory discoveries with clinical applications for global health advancement.

Profiles: Google Scholar | Scopus | ORCID | ResearchGate | LinkedIn

Featured Publications

1. Mohammad, I. S., He, W., & Yin, L. (2018). Understanding of human ATP binding cassette superfamily and novel multidrug resistance modulators to overcome MDR. Biomedicine & Pharmacotherapy, 100, 335–348. https://doi.org/10.1016/j.biopha.2018.02.028 Cited by: 226

2. Mohammad, I. S., Hu, H., Yin, L., & He, W. (2019). Drug nanocrystals: Fabrication methods and promising therapeutic applications. International Journal of Pharmaceutics, 562, 187–202. https://doi.org/10.1016/j.ijpharm.2019.03.055 Cited by: 163

3. Ishaq, H. M., Mohammad, I. S., Guo, H., Shahzad, M., Hou, Y. J., Ma, C., Naseem, Z., … (2017). Molecular estimation of alteration in intestinal microbial composition in Hashimoto’s thyroiditis patients. Biomedicine & Pharmacotherapy, 95, 865–874. https://doi.org/10.1016/j.biopha.2017.08.097 Cited by: 134

4. Wang, X., Mohammad, I. S., Fan, L., Zhao, Z., Nurunnabi, M., Sallam, M. A., Wu, J., … (2021). Delivery strategies of amphotericin B for invasive fungal infections. Acta Pharmaceutica Sinica B, 11(8), 2585–2604. https://doi.org/10.1016/j.apsb.2021.03.013 Cited by: 130

5. Gu, Y., Mohammad, I. S., & Liu, Z. (2020). Overview of the STAT-3 signaling pathway in cancer and the development of specific inhibitors. Oncology Letters, 19(4), 2585–2594. https://doi.org/10.3892/ol.2020.11309 Cited by: 120